Mar 2026 (Q1 FY26) — May 7, 2026
Crinetics Pharmaceuticals Q1 FY26 — Palsonify Launch Momentum and Pipeline Advancement
Read the full callCrinetics Pharmaceuticals (CRNX) earnings
- Jun 2026
- Mar 2026 (Q1 FY26)
- Dec 2025
Crinetics Pharmaceuticals earnings: last reported Thu, 7 May 2026, for the quarter ended Mar 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 25.1 | +2336.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -527.4 | +11995.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -121 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Guidance
What management said, and what became of it
9 of 9 judged targets kept · 14 open · verdicts reflect calls analysed to Mar 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Initiation of the Phase III trial of paltusotine in carcinoid syndrome | Initiate the carcinoid syndrome Phase III trial by the end of 2024 | Jun 2024 | We have also meaningfully advanced our deep clinical stage pipeline with 4 major trials running and recruiting nicely. | Achieved* |
| European commercial launch of PALSONIFY | Launch in Europe in 2026 | Jun 2025 | And just to be clear, we’re not preparing for revenue from international operations this year, but we will be prepared for early launch in 2027. | Delayed |
| Cash runway for the current operating plan | Fund the current operating plan into 2028 | Jun 2024 | we project that our existing cash and investments will be sufficient to fund our operations into 2030 | On Track |
14 of Crinetics Pharmaceuticals, Inc.'s 23 targets are still open. See which are on track and which have gone quiet. The 3 above are the free sample; 20 more targets are in the full ledger.
Claimed
- Palsonify generated $10.3 million in net product revenue for the quarter.
- 232 additional patient enrollment forms for Palsonify were secured in Q1 FY26.
- The unique prescriber base for Palsonify expanded to 263 as of March 31, up from over 125 at the end of 2023.
- Approximately 70% of Palsonify patients on therapy at the end of Q1 FY26 were reimbursed.
- Palsonify achieved over 60% payer coverage and is on track to exceed 75% by the end of Q3 FY26.
Qualified
Price
$84.95 0.00% · $0
Performance +174.1% 1Y
1Y: $30.99 on 29 Aug 2025 → $84.95. High $84.95 (31 Aug 2026), low $30.99 (29 Aug 2025).
- Previous close
- $84.95
- 52-week range
- $32.61 – $84.95
- One year
- +155.11%
Overview
- Symbol
- CRNX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
9 of 9 judged targets kept · 14 open · verdicts reflect calls analysed to Mar 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Initiation of the Phase III trial of paltusotine in carcinoid syndrome | Initiate the carcinoid syndrome Phase III trial by the end of 2024 | Jun 2024 | We have also meaningfully advanced our deep clinical stage pipeline with 4 major trials running and recruiting nicely. | Achieved* |
| European commercial launch of PALSONIFY | Launch in Europe in 2026 | Jun 2025 | And just to be clear, we’re not preparing for revenue from international operations this year, but we will be prepared for early launch in 2027. | Delayed |
| Cash runway for the current operating plan | Fund the current operating plan into 2028 | Jun 2024 | we project that our existing cash and investments will be sufficient to fund our operations into 2030 | On Track |
Claimed
- Palsonify generated $10.3 million in net product revenue for the quarter.
- 232 additional patient enrollment forms for Palsonify were secured in Q1 FY26.
- The unique prescriber base for Palsonify expanded to 263 as of March 31, up from over 125 at the end of 2023.
- Approximately 70% of Palsonify patients on therapy at the end of Q1 FY26 were reimbursed.
- Palsonify achieved over 60% payer coverage and is on track to exceed 75% by the end of Q3 FY26.
Qualified
The full ledger
Open Crinetics Pharmaceuticals, Inc.’s full ledger
A free account opens 5 company ledgers a month. All 23 tracked commitments, with each call’s wording and source.
Call summaries
Dec 2025 (Q4 FY25) — Feb 26, 2026
Crinetics Pharmaceuticals Q4 FY25 — PALSONIFY Launch Progress and Pipeline Advancement
Read the full callEvery analysed call
Crinetics Pharmaceuticals earnings calls (CRNX)
Financials
What the filings say
Net profit, year on year: −5% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 1 | 0 | 6 | 11 | 25 |
| Expenses | — | — | 112 | 130 | — | — | 151 | 158 |
| Operating profit | -88 | -95 | -111 | -129 | -143 | -134 | -140 | -132 |
| Operating margin | — | — | −30860.1% | −12523.0% | −99710.5% | −2169.6% | −1307.8% | −527.4% |
| Other income | 11 | 14 | 15 | 13 | 12 | 11 | 13 | 12 |
| Profit before tax | -77 | — | — | — | -130 | -123 | — | — |
| Net profit | -77 | -81 | -97 | -116 | -130 | -123 | -128 | -121 |
| EPS ($ per share) | -0.96 | — | -1.04 | -1.23 | -1.38 | — | -1.23 | -1.14 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 204 | 211 | 337 | 608 | 759 | 1,192 | 2,276 | 2,408 |
| Reserves | -43 | -94 | -168 | -275 | -439 | -654 | -952 | -1,417 |
| Total liabilities | 11 | 13 | 15 | 19 | 36 | 96 | 110 | 134 |
| Fixed assets | 4 | 4 | 3 | 3 | 4 | 11 | 12 | 14 |
| Investments | 119 | 78 | 78 | 133 | 302 | 504 | 1,090 | 926 |
| Total assets | 171 | 130 | 183 | 351 | 352 | 635 | 1,435 | 1,126 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -19 | -46 | -62 | -89 | -115 | -169 | -230 | -378 |
| Cash from investing | -119 | 42 | 0 | -56 | -174 | -200 | -575 | 174 |
| Cash from financing | 170 | 0 | 115 | 253 | 122 | 391 | 1,015 | 41 |
| Net cash flow | 31 | -5 | 53 | 108 | -167 | 22 | 210 | — |
| Capital expenditure | -1 | -0 | -0 | -0 | -2 | -5 | -4 | -6 |
| Free cash flow | -21 | -47 | -62 | -89 | -117 | -173 | -234 | -384 |
CRNX revenue by segment
| Segment | Q3 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|
| Reportable | 100% | 100% | 100% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
CRNX operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Change vs prior quarter |
|---|---|---|---|
| Enrollment forms received | 200+As we previously shared, in Q4, we received more than 200 enrollment forms.Source: earnings call transcript | 232As Scott mentioned, in the first quarter alone, we secured 232 new patient enrollment forms.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
90 filings between Nov 3, 2025 and Sep 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$6.51M
18 sales by 8 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 13
- Award — granted as compensation
- 13
- Option exercise — converted options into shares
Also filed: 32 dispositions to the issuer, 14 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Knight Jeff E. | — | $3.79M | Apr 8, 2026 |
| Struthers Richard Scott | — | $821.5K | Mar 16, 2026 |
| Pizzuti Dana | — | $438.4K | Dec 1, 2025 |
| Betz Stephen F. | — | $396.6K | Mar 16, 2026 |
| Okey Stephanie | — | $365.2K | Jun 17, 2026 |
| Vivaldi Coelho Rogerio | — | $300.8K | Jul 2, 2026 |
| Schilke Tobin | — | $266.3K | Mar 3, 2026 |
| Kalofonos Isabel | — | $137.5K | Jan 5, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Kalofonos Isabel Chief Commercial Officer | Disposition to issuer | 34,000 | $2.89M |
| Sep 1, 2026 | Schilke Tobin Chief Financial & Infra. Ofcr. | Disposition to issuer | 7,956 | $676.3K |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 176,663 | $15.02M |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 80,000 | $6.80M |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 111,100 | $9.44M |
| Sep 1, 2026 | Kalofonos Isabel Chief Commercial Officer | Disposition to issuer | 1,669 | $141.9K |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 111,100 | $9.44M |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 136,805 | $11.63M |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 111,100 | $9.44M |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 106,000 | $9.01M |
| Sep 1, 2026 | Betz Stephen F. Chief Scientific Officer | Disposition to issuer | 58,286 | $4.95M |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 1,000 | $85.0K |
| Sep 1, 2026 | Schilke Tobin Chief Financial & Infra. Ofcr. | Disposition to issuer | 71,471 | $6.08M |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 111,100 | $9.44M |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 100,000 | $8.50M |
| Sep 1, 2026 | Okey Stephanie Director | Disposition to issuer | 6,400 | $544.0K |
| Sep 1, 2026 | Deardorf Caren Director | Disposition to issuer | 5,925 | $503.6K |
| Sep 1, 2026 | Deardorf Caren Director | Disposition to issuer | 16,300 | $1.39M |
| Sep 1, 2026 | Nichols Weston Director | Disposition to issuer | 5,925 | $503.6K |
| Sep 1, 2026 | Fust Matthew K Director | Disposition to issuer | 22,836 | $1.94M |
| Sep 1, 2026 | Nichols Weston Director | Disposition to issuer | 16,300 | $1.39M |
| Sep 1, 2026 | Fust Matthew K Director | Disposition to issuer | 5,925 | $503.6K |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 110,000 | $9.35M |
| Sep 1, 2026 | Vivaldi Coelho Rogerio Director | Disposition to issuer | 13,300 | $1.13M |
| Sep 1, 2026 | Okey Stephanie Director | Disposition to issuer | 5,925 | $503.6K |
| Sep 1, 2026 | Bedrosian Camille L Director | Disposition to issuer | 5,925 | $503.6K |
| Sep 1, 2026 | Struthers Richard Scott President & CEO | Disposition to issuer | 248,043 | $21.08M |
| Sep 1, 2026 | Vivaldi Coelho Rogerio Director | Disposition to issuer | 5,925 | $503.6K |
| Sep 1, 2026 | WIERENGA WENDELL Director | Disposition to issuer | 5,925 | $503.6K |
| Sep 1, 2026 | WIERENGA WENDELL Director | Disposition to issuer | 116,146 | $9.87M |
| Sep 1, 2026 | Bedrosian Camille L Director | Disposition to issuer | 16,300 | $1.39M |
| Sep 1, 2026 | Betz Stephen F. Chief Scientific Officer | Disposition to issuer | 79,650 | $6.77M |
| Aug 20, 2026 | Schilke Tobin Chief Financial & Infra. Ofcr. | Award | 471 | $0 |
| Aug 7, 2026 | Struthers Richard Scott President & CEO | Option exercise | 3,969 | $100.0K |
| Aug 7, 2026 | Struthers Richard Scott President & CEO | Option exercise | 4,422 | $100.0K |
| Aug 7, 2026 | Struthers Richard Scott President & CEO | Option exercise | 4,995 | $100.0K |
| Aug 7, 2026 | Struthers Richard Scott President & CEO | Option exercise | 6,542 | $100.0K |
| Jul 2, 2026 | Vivaldi Coelho Rogerio Director | Sale 10b5-1 plan | 3,000 | $120.0K |
| Jun 18, 2026 | Fust Matthew K Director | Award | 5,925 | $0 |
| Jun 18, 2026 | Okey Stephanie Director | Award | 5,925 | $0 |
| Jun 18, 2026 | Deardorf Caren Director | Award | 5,925 | $0 |
| Jun 18, 2026 | Nichols Weston Director | Award | 5,925 | $0 |
| Jun 18, 2026 | Vivaldi Coelho Rogerio Director | Award | 5,925 | $0 |
| Jun 18, 2026 | Bedrosian Camille L Director | Award | 5,925 | $0 |
| Jun 18, 2026 | WIERENGA WENDELL Director | Award | 5,925 | $0 |
| Jun 17, 2026 | Okey Stephanie Director | Sale 10b5-1 plan | 608 | $22.0K |
| Jun 17, 2026 | Okey Stephanie Director | Sale 10b5-1 plan | 6,292 | $224.1K |
| May 29, 2026 | Struthers Richard Scott President & CEO | Gift | 111,100 | $0 |
| May 29, 2026 | Struthers Richard Scott President & CEO | Gift | 111,100 | $0 |
| May 29, 2026 | Struthers Richard Scott President & CEO | Gift | 111,100 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Crinetics Pharmaceuticals, Inc.
Free account. Everything above stays public.
Write why you follow Crinetics Pharmaceuticals, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading